Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes
NCT04532346Phase 1Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydroxychloroquine in interstitial lung disease (ILD) (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Oxygenation status at 12 months. Started Sep 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04532346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532346.